Melatonin, a natural hormone segregated by the own human body, is an excellent sleep regulator expected to replace somniferous, which are much more aggressive, to correct the sleep/wakefulness pace when human biological clock becomes altered.
Those are the conclusions of a research work carried out by Darío Acuña-Castroviejo and Germaine Escames, professors of the Institute of Biotechnology (Biomedical Research Centre of the University of Granada), who have been carrying out a complete analysis of the properties of this natural hormone segregated by the pineal gland for years.
Melatonin (frequently called the ‘hormone of darkness’, because the organism produces it at night) is currently being used by the pharmaceutical industry to design derivative synthetic medicines, a very interesting therapeutic tool for the treatment of sleep alterations. Not in vain, the European Medicines Agency (EMEA) authorized in 2007 the use of melatonin for this type of therapies, after years of debate about the convenience of this measure.
The authors of this work, published in the Revista de Neurología (2009), state that endogenous melatonin (this is, that segregated by the human organism) “plays an important role in the circadian regulation of sleep”, whereas exogenous melatonin (administered as a medicine) “has an influence on sleep aspects such as latency and quality”.
Actually, the ability of melatonin to readapt the biological clock has been studied in blind individuals, as they cannot make use of the information of the photoperiod to activate the endogenous pacemaker segregated by melatonin at night. The scientists have pointed out that the administration of melatonin every 24 hours (1-10 mg/a day) re-establishes the pace in these persons, including the sleep/wakefulness, synchronizing them to a period of 24 hours.
The use of melatonin to regulate sleep is not the only work carried out at the Institute of Biotechnology of the UGR. In the last years, professors Acuña and Escames have proved that this substance is also useful to slow down cell ageing, to treat diseases such as Parkinson and to slow down cell death caused by serious infectious processes that affect the entire organism technically known as sepsis. Exactly, they are working at present on a clinical test in Phase II to assess the therapeutic of melatonin in the septic shock on patients, funded by the Health Institute Carlos III.Reference: Professors Darío Acuña Castroviejo and Germaine Escames
Darío Acuña Castroviejo | EurekAlert!
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences